HJHuijie Jiang

Huijie Jiang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Huijie Jiang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Hailong Xu

    Department of Radiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China

    1 shared publication
  • Hao Jiang

    Department of Radiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China

    1 shared publication
  • Mingyu Zhang

    Department of Radiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China

    1 shared publication
  • Rongjun Zhang

    Jiangsu Institute of Nuclear Medicine, Wuxi, China

    1 shared publication
  • Wenbin Pan

    Department of Radiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China

    1 shared publication
  • Xiaolin Gao

    Department of Radiology, China-Japan Union Hospital, Jilin University, Changchun, China

    1 shared publication

Latest Publications

  • Open Access

    Near‐infrared fluorescence‐labeled anti‐PD‐L1‐mAb for tumor imaging in human colorectal cancer xenografted mice

    by Mingyu Zhang, Huijie Jiang, Rongjun Zhang, Hao Jiang, Hailong Xu, Wenbin Pan, Xiaolin Gao, Zhongqi Sun

    The expression of programmed death ligand‐1 (PD‐L1) in tumor has been used as a biomarker to predict the anti‐PD‐L1 immunotherapy response. To develop a noninvasive imaging technique to monitor the dynamic changes in PD‐L1 expression in colorectal cancer (CRC), we labeled an anti‐PD‐L1 monoclonal antibody with near‐infrared (NIR) dye and tested the ability of the NIR‐PD‐L1‐mAb probe to monitor the PD‐L1 expression in CRC‐xenografted mice by performing optical imaging. Consistent with the expression levels of PD‐L1 protein in three CRC cell lines in vitro by flow cytometry and Western blot analyses, our in vivo imaging showed the highest fluorescence signal of the xenografted tumors in mice bearing SW620 CRC cells, followed by tumors derived from SW480 and HCT8 cell lines. We detected the highest fluorescent intensity of the tumor at 120 hours after injection of NIR‐PD‐L1‐mAb. The highest fluorescence intensity was seen in the tumor, followed by the spleen and the liver in SW620 xenografted mice. In SW480 and HCT8 xenografted mice, however, the highest fluorescent signals were detected in the spleen, followed by the liver and the tumor. Our findings indicate that SW620 cells express a higher level of PD‐L1, and the NIR‐PD‐L1‐mAb binding to PD‐L1 on the surface of CRC cells was specific. The technique was safe and could provide valuable information on PD‐L1 expression of the tumor for development of a therapeutic strategy of personized targeted immunotherapies as well as treatment response of patients with CRC.